2 results
Approved WMOPending
Phase 1 - Primary Objective• To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of single-agent MCLA-129 in patients with NSCLC, GC/GEJ adenocarcinoma, HNSCC or ESCC, with disease progression after prior therapy for…
Approved WMORecruiting
Objective: The primary objective is to analyse whether LSCI could be integrated in a PAOD endovascular operation program in a HOT, for the visualisation of the microcirculation of the foot. Therefore, stability and reproducibility of the system,…